Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression

Respiratory Medicine and Research 2026

View at publisher
Authors: Paul Lajoinie, Vincent Fallet, Marie Wislez, Pauline du Rusquec, Valérie Gounant, Christos Chouaid, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Camille Mehlman
DOI: 10.1016/j.resmer.2026.101253
Cited by: 1
References: 16

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies HER2/EGFR in Cancer Research

Publication details

Journal / source
Respiratory Medicine and Research
Publisher
Elsevier BV
Volume
89
Pages
101253–101253
Publication date
3 February 2026
Language
EN